Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,030 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium.
Day JR, Larson MC, Durani U, Koff JL, Wang Y, Habermann TM, Lossos IS, Nastoupil LJ, Strouse CS, Chihara D, Martin P, Leonard JP, Cohen JB, Kahl BS, Ruan J, Burack R, Friedberg JW, Cerhan JR, Flowers CR, Link BL, Maurer MJ, Casulo C. Day JR, et al. Among authors: martin p. Blood Adv. 2024 Nov 27:bloodadvances.2024014053. doi: 10.1182/bloodadvances.2024014053. Online ahead of print. Blood Adv. 2024. PMID: 39602301
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. Cerhan JR, et al. Among authors: martin p. Am J Hematol. 2024 Mar;99(3):408-421. doi: 10.1002/ajh.27202. Epub 2024 Jan 13. Am J Hematol. 2024. PMID: 38217361
Defining primary refractory large B-cell lymphoma.
Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks T, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS. Bock AM, et al. Among authors: martin p. Blood Adv. 2024 Jul 9;8(13):3402-3415. doi: 10.1182/bloodadvances.2024012760. Blood Adv. 2024. PMID: 38669353 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112179
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis.
Abro B, Maurer MJ, Habermann TM, Burack WR, Chapman JR, Cohen JB, Friedberg JW, Inghirami G, Kahl BS, Larson MC, Link BK, Lossos IS, Martin P, McDonnell TJ, Nastoupil LJ, Riska SM, Syrbu S, Vega F, Vij KR, Flowers CR, Cerhan JR, Jaye DL, Feldman AL. Abro B, et al. Among authors: martin p. Blood. 2024 Nov 7;144(19):2063-2066. doi: 10.1182/blood.2024025681. Blood. 2024. PMID: 39255410
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M, Tsai NC, Palmer J, Armenian S, Chen R, Rosen S, Forman S, Popplewell L, Kwak L, Martin P, Maddocks K, Bond D, Herrera AF. Mei M, et al. Among authors: martin p. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):537-542. doi: 10.1016/j.clml.2024.03.013. Epub 2024 Apr 10. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38693037 Clinical Trial.
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J, Easwar Kumar V, Carrasco SE, Ouseph MM, Yamshon S, Martin P, Griess O, Shema E, Porazzi P, Ruella M, Brentjens RJ, Inghirami G, Zappasodi R, Chadburn A, Melnick AM, Béguelin W. Isshiki Y, et al. Among authors: martin p. Cancer Cell. 2024 Nov 30:S1535-6108(24)00441-0. doi: 10.1016/j.ccell.2024.11.006. Online ahead of print. Cancer Cell. 2024. PMID: 39642889
8,030 results